ESMO 2026: 5 Biotech Abstracts That Could Move Stocks

Update September 10, 2026: Summit (SMMT) has since moved to $17.54 (September 9 close), up ~20% from the $14.60 reference in this article, after Akeso reported HARMONi-2 met its overall survival secondary endpoint — see our HARMONi-2 OS coverage.

Update September 27, 2026: ESMO 2026 (Sept 17–21) has concluded, and Merck/Daiichi Sankyo withdrew the I-DXd BLA on September 25 — the “pre-PDUFA intelligence” section below is now moot (see our withdrawal coverage).

Every biotech investor knows ASCO moves stocks. Fewer screen ESMO systematically, and that creates an edge. ESMO 2026 runs September 17-21 in Madrid, with late-breaking abstract titles expected online by September 25 and full abstracts released in the weeks before. The trade happens at abstract release, not at the podium. If you wait for the presentation, the stock already moved.

The pattern repeats every conference season: a mid-cap biotech drops a dataset that surprises the Street, the stock gaps 15-30% overnight, and the mega-cap Keytruda updates that dominate headlines barely twitch. The edge is screening the small and mid-cap names where the data actually moves the needle. Here are five abstracts to watch, ranked by stock-moving potential.

1. Summit/Akeso Ivonescimab: HARMONi-6 NSCLC Update

Summit Therapeutics closed Tuesday at $14.60, a $11.65 billion market cap built almost entirely on ivonescimab, the PD-1/VEGF bispecific licensed from Akeso. The FDA assigned a November 14, 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC post-TKI progression, based on the HARMONi Phase 3 trial that showed a statistically significant PFS benefit over chemotherapy. That PDUFA alone is worth the market cap. ESMO is the next data drop.

The abstract to screen for: updated HARMONi-6 data in first-line NSCLC, or HARMONi-GI1 biliary tract cancer overall survival. HARMONi-6 pits ivonescimab plus chemo against placebo plus chemo in treatment-naive patients, and if it shows a PFS benefit comparable to HARMONi, the market will price ivonescimab as a first-line contender, not just a post-TKI niche drug. That expands the peak sales estimate from $3-4 billion to $8-10 billion. A HARMONi-GI1 OS win in BTC adds a second indication and further validates the bispecific platform.

The risk: ivonescimab’s China-only Phase 3 HARMONi-A already raised questions about whether the Western population shows the same magnitude of benefit. The PDUFA review will answer that. ESMO data that underperforms HARMONi-A in any subgroup would drop SMMT 20% overnight. If the data matches or exceeds, Summit re-rates toward $15-18 billion. The ivonescimab BTC data and the broader oncology catalyst calendar are covered; ESMO is the next checkpoint.

2. Merck/Daiichi Sankyo I-DXd: Pre-PDUFA Intelligence

I-DXd (ifinatamab deruxtecan), the B7-H3-targeting ADC from Merck and Daiichi Sankyo, had an October 10 PDUFA for previously treated extensive-stage small cell lung cancer, but the BLA was withdrawn on September 25 after the FDA said the Phase 2 IDeate-Lung01 data do not support accelerated approval (see our withdrawal coverage). The pre-PDUFA intelligence framing below is now moot.

The Phase 2 IDeate-Lung01 trial data is the benchmark: 48.2% confirmed ORR at 12 mg/kg, with a 56.3% ORR in the second-line subset, median PFS of 4.9 months, and median OS of 10.3 months. These numbers are substantially better than topotecan’s 9.4% ORR and lurbinectedin’s 13% in the same setting. The FDA granted Breakthrough Therapy designation in August 2025 and accepted the BLA with priority review.

For Merck at $323 billion market cap, I-DXd approval adds maybe $1-2 billion in peak sales: a rounding error. The stock won’t move on an SCLC approval. But the ESMO data matters for the Daiichi Sankyo ADC partnership, which has been troubled. Patritumab deruxtecan (HER3-DXd) failed to win FDA approval in NSCLC and the application was pulled after underwhelming Phase 3 OS data. I-DXd is now the second DXd asset to be pulled from FDA review, in a collaboration Merck paid $4 billion upfront to enter. The I-DXd withdrawal and the earlier PDUFA setup cover both sides of the story.

3. BridgeBio BBO-11818: The Pan-KRAS Phase 1 Update

BridgeBio Oncology (ticker: BBIO) closed at $76.50, a $14.96 billion market cap. The company has three approved drugs (Attruby for ATTR-CM, acoramidis franchise) generating commercial revenue, but the pipeline catalyst that moves the stock is BBO-11818, the pan-KRAS inhibitor in Phase 1.

BridgeBio has guided to updated Phase 1 KONQUER-101 data in the second half of 2026, and ESMO is the obvious venue. The drug targets all major KRAS mutations (G12C, G12D, G12V, G12R, G13D) with a single noncovalent inhibitor. Amgen’s Lumakras and Mirati’s Krazati only hit G12C, which is about 13% of NSCLC. A pan-KRAS inhibitor covers 25-30% of all solid tumors, including pancreatic (95% KRAS-mutant), colorectal (45%), and NSCLC (30%). ClinicalTrials.gov NCT06917079 shows KONQUER-101 is enrolling across monotherapy and 10 combination cohorts including pembrolizumab, cetuximab, and chemotherapy backbones.

The FDA granted Fast Track designation in KRAS-mutant pancreatic cancer, where there are zero approved targeted therapies. If the Phase 1 data shows even a 30% ORR in pancreatic cancer, that is best-in-class and registrational. The existing published pan KRAS primer on the site breaks down the competitive picture against Revolution Medicines’ RAS(ON) inhibitors. ESMO is the first clinical data update since the KONQUER-101 enrollment expanded.

4. GSK Jemperli: Rectal Cancer sBLA Momentum

GSK at $50.44 has one of the more interesting oncology setups at ESMO: the Jemperli (dostarlimab) rectal cancer sBLA was accepted with priority review, and ESMO could feature updated data from the Memorial Sloan Kettering cohort where 100% of mismatch repair-deficient (dMMR) locally advanced rectal cancer patients achieved a clinical complete response without chemoradiation or surgery. That dataset, if expanded to a larger cohort, would redefine rectal cancer treatment.

For GSK at $96 billion market cap, Jemperli’s rectal cancer indication adds $500-800 million in peak sales. It’s not a stock-mover at that scale, but the data strength at ESMO determines whether Jemperli captures the dMMR rectal cancer market outright or splits it with Merck’s Keytruda, which has its own dMMR rectal cancer program. The Jemperli sBLA acceptance was covered in June. ESMO will show whether the dataset is strong enough to make this a standard-of-care shift or an incremental label expansion.

5. GSK Jideytro: Already Approved, Already Priced

The original version of this list included Nuvalent’s zidesamtinib as a Sept 18 PDUFA play, with ESMO falling during the PDUFA window. That catalyst is consumed. The FDA approved zidesamtinib as Jideytro on July 22, two months ahead of schedule, and GSK acquired Nuvalent for $10.6 billion. The drug is on the market, the stock already priced it, and any ESMO data on zidesamtinib is post-hoc confirmation of what the FDA already reviewed.

The lesson is broader: screening ESMO for PDUFA-adjacent catalysts only works when the PDUFA hasn’t already happened. Between the brief’s creation and the conference, early approvals consume catalysts. The same applies to any pre-PDUFA ESMO play: verify the approval status before you trade the abstract.

The Mega-Cap Filter

This list intentionally excludes the Keytruda, Opdivo, and Tagrisso updates that dominate ESMO headlines. Those updates move zero basis points on $150-300 billion market caps. The filter is simple: if the company’s market cap exceeds $100 billion and the indication is a single tumor type, the data won’t move the stock.

Summit at $11.65 billion and BridgeBio at $14.96 billion are the two names where one ESMO abstract can re-rate the stock 15-30%. Both have binary data setups: ivonescimab’s first-line NSCLC data determines whether the drug is a niche post-TKI product or a frontline standard of care, and BBO-11818’s Phase 1 pan-KRAS data determines whether BridgeBio has a pipeline catalyst beyond its commercial Attruby franchise.

The conference trading playbook is straightforward and is detailed in the biotech conference trading guide. Abstract release is the trade date. By the time the presenter steps to the podium, the stock has already moved. Position size: 1-2% of portfolio per binary event. IV crush after the abstract drop is real: options premium collapses whether the data is good or bad. The 24-hour rule applies: don’t hold a conference catalyst position past the first trading day after abstract release unless you have a thesis on the follow-up data that hasn’t been priced.

The verdict: screen for the Summit and BridgeBio abstracts first. Those are the two names where ESMO 2026 data actually re-rates the stock. Everything else is confirmation of what the market already knows.